Liver autoantigens

Liver autoantigens comprise a heterogeneous group of endogenous proteins targeted by the immune system in autoimmune liver diseases (AILD), such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Key specific autoantigens include the pyruvate dehydrogenase complex E2 subunit (PDC-E2) in PBC and cytochrome P450 2D6 (CYP2D6) or soluble liver antigen (SLA) in AIH. These proteins normally function as vital enzymes in metabolic pathways within hepatocytes and cholangiocytes, but in pathological states, the breakdown of immunological tolerance leads to their recognition by autoreactive T-cells and the production of diagnostic autoantibodies. While these autoantigens currently serve primarily as essential diagnostic biomarkers, they are the focus of emerging research into antigen-specific immunotherapies, such as tolerogenic nanoparticles (e.g., CNP-101) designed to restore immune tolerance without the need for systemic immunosuppression. Standard clinical management currently relies on non-specific drugs like corticosteroids (prednisone) and antimetabolites (azathioprine) to suppress the inflammatory cascade triggered by the immune response to these antigens. Chronic exposure to these triggers can lead to progressive interface hepatitis, bile duct destruction, and eventually cirrhosis if left untreated.

Other names

Hepatic autoantigensLiver-specific antigensAILD antigens

Broad systemic immunosuppression to suppress autoreactive T-cell and B-cell responses against liver tissue; experimental induction of antigen-specific immune tolerance through tolerogenic nanoparticles or vaccines.